Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2021

01-06-2021 | Hepatocellular Carcinoma | Stanford Multidisciplinary Seminars

Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus

Authors: John R. Bergquist, Amy Y. Li, Chris S. Javadi, Ranjit S. Chima, Joseph S. Frye, Brendan C. Visser

Published in: Digestive Diseases and Sciences | Issue 6/2021

Login to get access

Excerpt

A 42-year-old man with a history of chronic hepatitis B, maintained on tenofovir, was evaluated for cough and shortness of breath. After initial evaluation in the outpatient setting demonstrated a large right-sided pleural effusion, he was seen at his local Emergency Department where CT and subsequent MR identified a large (22.2 cm) Liver Reporting and Data System (LI-RADS) 5 mass occupying the right hepatic lobe (Fig. 1) that exhibited arterial-phase hyperenhancement, washout, and an enhancing pseudo-capsule. An enhancing tumor thrombus was also visible within the right main portal vein. Further evaluation identified an alpha fetoprotein (AFP) of 34,000 and a history of unintentional 15 lbs weight loss over a period of months. As a result of the large mass, the patient required multiple drainages for recurrent pleural effusions. He was empirically started on anti-vascular endothelial growth factor (VEGF) therapy with lenvatinib and referred to interventional radiology for consideration of radioembolization, but this was deferred due to an elevated shunt fraction, with approximately 3.6% shunting to the lungs. The patient was then referred for consideration of resection. Other than hepatitis B, he had no other pertinent medical history.
Literature
8.
go back to reference Tsilimigras DI, Bagante F, Sahara K, Moris D, Hyer JM, Wu L, Ratti F, Marques HP, et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification. Ann Surg Oncol. 2019;26:3693–3700. https://doi.org/10.1245/s10434-019-07580-9.CrossRefPubMed Tsilimigras DI, Bagante F, Sahara K, Moris D, Hyer JM, Wu L, Ratti F, Marques HP, et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification. Ann Surg Oncol. 2019;26:3693–3700. https://​doi.​org/​10.​1245/​s10434-019-07580-9.CrossRefPubMed
17.
go back to reference Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870. https://doi.org/10.1016/S1470-2045(15)00050-9.CrossRefPubMed Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870. https://​doi.​org/​10.​1016/​S1470-2045(15)00050-9.CrossRefPubMed
Metadata
Title
Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus
Authors
John R. Bergquist
Amy Y. Li
Chris S. Javadi
Ranjit S. Chima
Joseph S. Frye
Brendan C. Visser
Publication date
01-06-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06682-9

Other articles of this Issue 6/2021

Digestive Diseases and Sciences 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.